Several EGFR-TKIs, including gefitinib, erlotinib, afatinib, and osimertinib, have been developed and approved for first-line treatment of advanced NSCLC harboring EGFR-activating mutations [11]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.